


Supplementary Materials

Table S1. Comparisons of SARS-CoV-2 S protein antibody levels by three chemiluminescent immunoassays (Abbott, Roche and Siemens) and the surrogate virus neutralization test (Genscript) in COVID-19 patients according to days after symptom onset and disease severity

		Days after symptom onset						
		Severity	≤5	6-8	9-11	12-14	15-21	22≤
Abbot (AU/mL)	severe or critical	5.1†	17.6	1128.4	4670.2*	7621.6*	6615.8*	
		(1.7- 231.1)	(3.9- 2117.0)	(256.4- 6656.0)	(1184.2- 7892.3)	(3900.6- 11323.4)	(3855.8- 7856.7)	
		mild	6.5 (0.9- 87.3)	13.1 (3.7- 128.4)	95.5 (25.5- 722.7)	1247.6 (181.1- 2628.1)	955.7 (162.7- 3573.2)	3002.6 (309.0- 6552.7)
	Roche (U/mL)	severe or critical	0.4 (0.4-4.5)	0.4 (0.4- 49.3)	11.7 (2.1- 130.5)	72.9 (19.6- 160.5)	184.0 (148.3- 386.4)	199.5 (129.1- 378.6)
		mild	0.4 (0.4- 0.9)	0.5 (0.4- 14.2)	4.1 (0.5- 43.6)	62.6 (3.0- 101.7)	64.7 (2.8- 130.6)	89.7 (7.9- 715.9)
		Siemens (U/mL)	0.1 (0.0-1.6)	0.2 (0.0- 12.5)	7.2* (1.9- 45.2)	31.1* (9.4- 53.5)	72.8* (36.9- 95.5)	49.5* (34.7- 95.7)
Genscript (%)	severe or critical	0.1 (0.0-1.6)	0.2 (0.0- 12.5)	1.1 (0.1-4.9)	7.4 (1.1- 22.5)	8.5 (0.9- 22.8)	19.1 (1.7- 61.2)	
		mild	0.1 (0.0-0.9)	0.2 (0.0-0.8)	1.1 (0.1-4.9)	7.4 (1.1- 22.5)	8.5 (0.9- 22.8)	19.1 (1.7- 61.2)
		Genscript (%)	11.0 (3.0- 42.5)	28.0 (7.4- 78.5)	71.0 (47.8- 87.3)	90.0 (65.3- 93.0)	92.0 (86.9- 95.0)	88.5 (85.0- 95.0)
	mild	severe or critical	13.0 (8.2- 19.8)	13.0 (2.5- 59.4)	40.0 (17.3- 80.1)	82.5 (31.5- 90.1)	82.0 (36.1- 92.2)	89.5 (47.2- 94.8)
		severe or critical	13.0 (8.2- 19.8)	13.0 (2.5- 59.4)	40.0 (17.3- 80.1)	82.5 (31.5- 90.1)	82.0 (36.1- 92.2)	89.5 (47.2- 94.8)
		mild	13.0 (8.2- 19.8)	13.0 (2.5- 59.4)	40.0 (17.3- 80.1)	82.5 (31.5- 90.1)	82.0 (36.1- 92.2)	89.5 (47.2- 94.8)

*Severe or critical vs. mild ($p < 0.05$). †Median (95% confidence interval)








Figure S1. SARS-CoV-2 S protein antibody levels measured by three chemiluminescent immunoassays and the surrogate virus neutralization test in 32 COVID-19 patients. Antibody levels are plotted according to days after symptom onset and disease course (critical, severe, or mild) in each assay.






Figure S2. Spearman rank correlation between SARS-CoV-2 S protein antibody levels from three chemiluminescent assays.